Launched in response to recent budget constraints across the scientific community, this initiative was created to support researchers by offering free sequencing reads — a reflection of our deep commitment to advancing discovery and innovation in the research community.
Thanks to the overwhelming response we received, we are delighted to share we were able to increase our support from 3 trillion to 4 trillion free reads!
The range of proposed research is impressive, spanning cancer biology, human genetics, microbiology, model organisms, and agricultural species, covering a diverse range of applications
We are inspired by your innovation, resilience, and drive — and we’re proud to play a small part in supporting your science.
We’re proud to have been chosen by Ultima Genomics, from a competitive pool of applicants, to receive complimentary sequencing through the "Counts on Us" initiative. We’re excited to see how Ultima can enhance our capabilities as an Olink Certified Service Provider to deliver high-quality, data-rich services to our clients more efficiently. We’re thrilled to contribute to this innovative program and look forward to continued partnership on future screening projects.
Mariam IskilovaLTRI at Mout Sinai Hospital
At the Leshchiner Lab, we focus on cancer computational biology and cancer genetics. We apply new genomic technologies, computational analysis and AI methods on data from patients' tumors to understand the biology behind tumor development, treatment evasions, and progress to metastisis. Because we work with cfDNA requiring deep sequencing, we are eager to explore a more cost-effective, high-quality NGS technology to support our research needs. We are excited our project was chosen for the “Count on Us” initiative and hope to continue more projects using the Ultima platform in the future.
Ignaty Leshchiner, PhDBoston University School of Medicine
I’m incredibly excited and grateful for the support of the “Count on Us” initiative. Thrilled to be involved in the first transcriptomic dataset capturing how intestinal fibrosis starts and progresses in Crohn’s disease-like in vivo models, which has the potential to bring us closer to breakthroughs for IBD patients. This incredible support is a game-changer for my career and a unique chance to unlock insights for the entire IBD research community by tackling a process impossible to study directly in patients.
Stefania De Santis, PhDCase Western Reserve University
In the Humphrey Lab, we're pushing the limits of single-cell transcriptomics to study neurodegenerative disease. Through the "Count on Us" initiative, Ultima is empowering us to sequence patient brain samples far more deeply than before to uncover pathological changes in mRNA splicing in frontotemporal dementia. We're using Ultima to sequence over a million single cells sorted from patient brains at unprecedented sequencing coverage and depth. Our goal is to use the dataset to identify splicing changes in specific neuronal populations, identify new biomarkers of disease, and uncover the links between protein pathology and neuronal health.
Jack Humphrey, PhDMt. Sinai School of Medicine
You Can Continue to Count on Us!
We look forward to seeing your research move forward...
Start your next Sequencing Project with the help of our Certified Service Providers
